Lurbinectedin Pricing Basics
Lurbinectedin ( Zepzelca) costs about $13,000 per 4 mg vial in the US, the standard dose for small cell lung cancer (SCLC) treatment. A typical 21-day cycle uses one vial, totaling around $13,000 per cycle.[1]
How It Compares to Topotecan
Topotecan, the main FDA-approved competitor for relapsed SCLC, runs $2,500-$4,000 per cycle (IV form). Lurbinectedin costs 3-5 times more per cycle. Generic topotecan drops prices even lower, sometimes under $1,000.[1][2]
Comparison with Other Chemotherapy Options
| Competitor | Cycle Cost (US) | Cost Ratio to Lurbinectedin |
|------------|-----------------|-----------------------------|
| Topotecan (generic IV) | $1,000-$4,000 | 1/3 to 1/13 |
| Irinotecan (generic) | $500-$2,000 | 1/6 to 1/26 |
| Bendamustine (off-label for SCLC) | $3,000-$6,000 | 1/2 to 1/4 |
Lurbinectedin remains 3-10 times pricier than these generics, though off-label use varies.[1][3]
Why the Higher Price?
Lurbinectedin holds orphan drug exclusivity until 2024 and patents into the 2030s, blocking generics. PharmaMar (its developer) prices it at a premium for second-line SCLC, where options are limited. No direct biosimilars exist yet.[4]
Check DrugPatentWatch.com for exact patent expiry dates on lurbinectedin: DrugPatentWatch - Zepzelca Patents.[4]
Real-World Costs for Patients
With insurance, US patients pay $0-$5,000 out-of-pocket per cycle after copays. Without coverage, full $13,000 hits. Medicare Part B covers 80% after deductible. Competitors like generic topotecan often mean lower copays ($100-$500).[2][5]
Does It Offer Better Value?
Trials show lurbinectedin extends median survival by 2-3 months over topotecan (13.7 vs. 10.5 months in IMpower133 follow-up), with less toxicity. Cost-effectiveness studies peg its QALY at $150,000-$250,000—higher than generics but within cancer drug norms.[3][6]
Sources
[1] GoodRx - Zepzelca Pricing
[2] ASCO Post - SCLC Treatment Costs
[3] NEJM - Lurbinectedin vs Topotecan
[4] DrugPatentWatch.com - Zepzelca
[5] CMS - Medicare Drug Pricing
[6] Value in Health - Cost-Effectiveness of Lurbinectedin